Session Information
Date: Wednesday, September 25, 2019
Session Title: Cognition and Cognitive Disorders
Session Time: 1:15pm-2:45pm
Location: Agora 3 East, Level 3
Objective: To compare amyloid distribution in patients with Parkinson´s disease (PD) with visual hallucinations (VH-p) and without (VH-n).
Background: In patients with PD the prevalence of VH has been reported between 6 and 74%. Their content is really variable, and can range from passage and sense of presence to well-structured visual experiences. It has been shown that mild cognitive impairment in PD and VH, are both risk factors for dementia. In turn, PD-Dementia patients have amyloid-β deposits that have a synergic effect with α synuclein, responsible for dementia, but the role of amyloid-β deposits in VH-p remains unknown.
Method: Twenty-three non-demented PD patients (8 VH-p and 15 VH-n) underwent a neuropsychological, neurological examinations and 18F-Flutemetamol PET-MRI. They were classified as VH-p and VH-n using the MDS-UPDRS-I. Standardized uptake value ratio (SUVr) change was computed across 8 bilateral volumes of interest.
Results: Both groups showed no significant differences in clinical characteristics but their cognitive status differ, counting 6.7% of MCI in the VH-n group and 50% in the VH-p group. VH-p patients had an increased SUVr in right posterior cingulate (p=0.047) and right and left frontal regions (p= 0.047 and 0.013 respectively) compared to VH-n patients.
Conclusion: Patients VH-p seem to present a higher burden of amyloid-β in right posterior cingulate and frontal cortex. This observation could be related to the onset of VH in PD. Further studies with a higher number of patients should be done, to avoid the possible influence of MCI on the results.
To cite this abstract in AMA style:
B. Fernández-Rodríguez, C. Gasca-Salas, R. Rodríguez-Rojas, P. Guida, D. Mata-Marín, I. Obeso-Martín, L. Vela, M. Garcerant-Tafur, L. García-Cañamaque, JA. Obeso. Visual hallucinations in Parkinson´s disease and amyloid burden: 18F-Flutemetamol PET-MRI study [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/visual-hallucinations-in-parkinsons-disease-and-amyloid-burden-18f-flutemetamol-pet-mri-study/. Accessed November 21, 2024.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/visual-hallucinations-in-parkinsons-disease-and-amyloid-burden-18f-flutemetamol-pet-mri-study/